FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to gastroenterology, and deals with application of conjugate of interferon with water-soluble polymer in combination with ribavirin and cyclosporine A for preparation of medication intended for treatment of HCV-induced infection. Invention ensures efficient impact in patients with HCV infection who initially did not respond to monotherapy with pegylated interferon, as well as combination of interferon A with ribavirin or interferon with cyclosporin A.
EFFECT: claimed method of application of cyclosporine and pagylated interferon combination.
14 cl
Title | Year | Author | Number |
---|---|---|---|
APPLICATION OF MODIFIED CYCLOSPORINS FOR TREATING HCV INDUCED DISEASES | 2004 |
|
RU2389501C2 |
METHOD OF VIRUS INFECTION TREATMENT | 2004 |
|
RU2371195C2 |
USE OF MODIFIED CYCLOSPORINES | 2007 |
|
RU2463071C2 |
USING TYPE III PEGYLATED INTERFERONS FOR TREATING HEPATITIS C | 2009 |
|
RU2496514C2 |
SINGLE NUCLEOTIDE POLYMORPHISMS FOR PREDICTING RESULTS OF TREATMENT OF HEPATIC C VIRUS INFECTION | 2011 |
|
RU2567663C2 |
SINGLE NUCLEOTIDE POLYMORPHISM ON CHROMOSOME 15 ENABLING PREDICTION OF HCV TREATMENT RESPONSES | 2012 |
|
RU2606759C2 |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTION | 2006 |
|
RU2440822C2 |
SILIBILIN COMPONENT FOR TREATING HEPATITIS | 2008 |
|
RU2482844C2 |
METHOD OF TREATING CHRONIC VIRAL HEPATITIS C WITH MEDICATIONS IN LIPOSOMAL FORM | 2011 |
|
RU2475263C1 |
DOSAGE FORMS | 2005 |
|
RU2393863C2 |
Authors
Dates
2010-07-20—Published
2005-07-13—Filed